Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross‐sectional survey

Liao, Ning; Lin, Wan-Ying; Hu, Xingbin; Fan, Rong; Liang, Xinling; Wu, Yin; Shen, Si; Yu, Rui; Sun, Jian; Hou, Jinlin

doi:10.1111/jvh.12733

Cited by 11 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One area of concern is renal function and a close association has been reported between CHB and chronic renal disease. [ 1 ] Chronic HBV infection can cause renal dysfunction through immune complex mediated glomerular diseases, such as membranous nephropathy. [ 2 ] In countries with endemic HBV infection, HBV-related glomerulopathies are an important cause of end-stage renal disease and renal replacement therapy.…”

Section: Introductionmentioning

confidence: 99%

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B

Liu

2018

Medicine

View full text Add to dashboard Cite

Background:Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) and/or interferon alfa (IFN-α) therapies have previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos (t)ide analogues (NAs) and IFN-α. The aim of this analysis was to assess the renal function during combined therapy with pegylated interferon α-2b (PEG-IFN-α-2b) and ADV versus PEG-IFN-α-2b alone in patients with chronic hepatitis B (CHB).Methods:We performed a multicenter, prospective, open-label, randomized-controlled trial of renal function data to investigate the efficacy of 48 weeks of therapy with PEG-IFN-α-2b and ADV versus PEG-IFN-α-2b alone in 102 patients with CHB in Anhui, China. Glomerular filtration rates (GFRs) were calculated by Cockcroft–Gault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study, and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and were tested by repeated-measures 1-way analysis of variance within groups. A linear mixed effects model for repeated measures was also used to evaluate the association between baseline information and estimated glomerular filtration rate (eGFR) changes overtime in all enrolled patients. The model considered the baseline age, sex, HBV DNA, aminotransferase, treatment group, time, and group-by-time interaction as fixed effects and incorporated random effects for individual subjects.Results:After 48 weeks of therapy and further 24 weeks of follow-up, the eGFR decreased both in patients given PEG-IFN-α-2b single therapy and combined therapy. Age, HBV DNA, and combined therapy were significant negative predictive factors for eGFR changes.Conclusion:The incidence of renal adverse events in both groups was low, and the combination therapy may have delayed, but reversible renal impairment.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B

Liu

2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Males were identi ed to be at greater risk by 77% [15]. A single-center cross-sectional study by Ning et al [16] indicated that among 1985 patients received antiviral therapy, 7.9% of whom were diagnosed with chronic kidney disease. At the same time, the diagnosis of HBV infection with renal disease not only acutely affects the prognosis of patients, but also increases the risk of death [17].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Entecavir for Hepatitis B virus-associated Glomerulonephritis with renal function insufficient

et al. 2021

Preprint

View full text Add to dashboard Cite

Background HBV-GN is one of the most common secondary kidney diseases in China. Entecavir is one of the first-line antiviral nucleoside drugs at present, which can also effectively apply to antiviral therapy for HBV-GN.Objective The retrospective study to explore whether the entecavir is efficacy and safety for the treatment of Hepatitis B virus-associated glomerulonephritis(HBV-GN) with renal function insufficient.Methods We screened patients diagnosed with HBV-GN in The Affiliated Hospital of Qingdao University, elevated serum creatinine at 130umol/l ~ 250umol/l. Group 1 (30 patients) was given entecavir as antiviral treatment. Group 2 (28 patients) was treated with angiotensin II receptor blocker (ARB). The changes of renal function and the possible influencing factors were observed, with a mean follow-up time of 36 months.Results Baseline demographic and clinical parameters were not different between the 2 groups. For both cohorts, serum creatinine levels were increased gradually and the levels of eGFR declined progressively during the follow-up. At the end of the follow-up, serum creatinine levels in group 1 (t = 1.64, P = 0.1) and in group 2 ( t = 4.35, P = 0.001) were considered statistically significant compared to baseline creatinine. The levels of eGFR in group 1 (t = 2.37, P = 0.0018) and in group 2 ( t = 4.35, P = 0.001) were considered statistically significant compared to baseline eGFR. Comparison between the two groups showed that the elevated serum creatinine level and reduction in the level of eGFR were significantly lower in group 1 (t = 2.67, P = 0.008) than in group 2 (t = 2.76, P = 0.006), which were considered statistically significant. At the same time, cumulative renal survival, using end-stage renal disease (ESRD, eGFR < 15ml/min) as the primary renal endpoint, was 96.7% in group 1 and 67.9% in group 2 respectively (P = 0.005). Meanwhile, urine protein excretion was significantly decreased in both groups compared with baseline values, group 1 (t = 5.74, P = 0.001) and group 2 (t = 4.27, P = 0.001), while no significant difference was found(P = 0.370)in both groups. We performed a multivariate Cox regression analysis required eGFR < 15ml/min as the primary end point, then we found that the entecavir treatment and remission of proteinuria were the protective factors of renal function impairment, while the lower baseline eGFR was the risk factor of the progression of ESRD.Conclusion Entecavir treatment slows the progression of renal function impairment in HBV-GN, meanwhile, entecavir shows a significantly renal protective effect.

show abstract

“…13 Epidemiological characteristics of CKD in the HBV-infected population usually vary among the different countries and areas. 14 The frequency of CKD is rather low in the USA and Western European countries, in which low prevalence rates of HBV have been reported. 4,15 In China, genotype C is the predominant HBV genotype in the northeastern region, while genotype B is in the central southern region, genotypes B and C in the southwestern region, and the recombinant genotype C/D in the northwestern region.…”

Section: Introductionmentioning

confidence: 99%

“…In China, Hou et al 14 demonstrated that hypertension, diabetes mellitus and cirrhosis were independent factors for the incidence of CKD, as determined through their singlecenter, cross-sectional study in which all patients received anti-HBV therapy. However, there are still few reports on the prevalence of CKD in patients with chronic HBV infection in the north area of China.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors of Chronic Kidney Disease in Chronic Hepatitis B: A Hospital-based Case-control Study from China

Liu¹,

Wang²,

Xu³

et al. 2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

Background and Aims: Chronic kidney disease (CKD) usually occurs during the chronic infection of hepatitis B virus (HBV). However, the risk factors of CKD in an HBV population have not been completely demonstrated. Our present study aimed to investigate the risk factors of CKD in chronic HBV infection using a hospital based cross-sectional study in the northern area of China. Methods: During January 2013 to December 2017, a total of 94 patients with CKD complicated by chronic HBV infection were consecutively enrolled in the study, as well as 548 age-and sex-matched hepatitis B patients without CKD who were enrolled as controls. Univariate and multivariate regression analyses were used to determine the effects of each variable after adjusting for cofounding factors. Results: Multivariate analysis showed that HBeAg-positive status (odds ratio [OR]=2.099, 95% CI 1.128-3.907), dyslipidemia (OR: 3.025, 95% CI 1.747-5.239), and hypertension (OR: 12.523, 95% CI 6.283-24.958) were independently associated with the incidence of CKD, while duration of HBV infection (≥240 months) (OR: 0.401, 95% CI 0.179-0.894), Log 10 HBsAg (OR: 0.514, 95% CI 0.336-0.786), and coronary heart disease (OR: 0.078, 95% CI 0.008-0.768) were protective factors for the incidence of CKD. Duration of HBV infection, Log 10 HBsAg, HBeAg-positive status and dyslipidemia remained the risk factors for CKD after adjusting for diabetes mellitus, hypertension, and coronary heart disease. Conclusions: Duration of HBV infection, Log 10 HBsAg, HBeAg-positive status and dyslipidemia contributed to the incidence of CKD during chronic HBV infection in a Chinese population.

show abstract

Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross‐sectional survey

Cited by 11 publications

References 41 publications

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B

Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B

Efficacy and safety of Entecavir for Hepatitis B virus-associated Glomerulonephritis with renal function insufficient

Risk Factors of Chronic Kidney Disease in Chronic Hepatitis B: A Hospital-based Case-control Study from China

Contact Info

Product

Resources

About